SIGNAL TRANSDUCTION FROM THE T CELL ANTIGEN RECEPTOR
SIGNAL TRANSDUCTION FROM THE T CELL ANTIGEN RECEPTOR
批准号:
2701553
负责人:
ROBERT T ABRAHAM
金额:
$4.96万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1992
资助国家:
美国
项目状态:
已结题
起止时间:
1992-05-01 至 1998-10-31
中文摘要
描述:针对大多数外来病毒的免疫反应的产生
病原体或宿主来源的癌细胞严重依赖于
T细胞活化和增殖的初始阶段。激活T细胞
细胞的产生是因为TCR能够结合抗原肽
与主要组织相容性复合体编码的分子络合,以及
将这种细胞外刺激传递给细胞内信号
机械设备。从配体结合的TCR启动的信号涉及
Src家族(Lck、Fyn)和Syk家族(ZAP-70)的顺序激活
蛋白酪氨酸激酶(PTKs)。这些TCR调节的PTK,在Tm中,
催化磷酸化事件,导致激活
磷脂酶PLC-γ-L、RAS和磷脂酰肌醇-3激酶
(PI-3K)。尽管我们在理解上取得了令人瞩目的进步
TCR的功能近年来,这种受体的机制
偶联到下游信号蛋白,以及相关的贡献
在T细胞激活程序的这些蛋白质中,只有部分
明白了。
为了进一步定义TCR介导的信号转导过程,Dr。
亚伯拉罕的团队创造了一套新的细胞和分子
将允许应用强大的基因方法的试剂
受体后信号转导的几个关键成分分析
机械设备。人类T白血病细胞系Jurkat被选为
为拟议的研究建立了完善的基础模型体系。这个
TCR信令功能的主要读数将是一个原型
TCR参与的核反应,即IL-2基因
表情。建议项目的具体目标是:(1)
ZAP-70的激活机制及该蛋白酪氨酸激酶的作用研究
以ZAP-70阴性Jurkat突变体为细胞的TCR信号转导
模型系统。(2)明确PLC-伽马-L的激活机制
通过TCR,并确定各种PLC的贡献-伽马-L
该酶在T细胞中的信号功能亚区
激活。(3)探讨PLC-伽马-L、RAS和PI-3K在细胞周期中的作用
以病毒来源的癌蛋白为靶点转录IL-2基因
T细胞中的多功能信号转导。
英文摘要
DESCRIPTION: The generation of immune responses against most foreign
pathogens or host-derived cancer cells is critically dependent on an
initial phase of T-cell activation and proliferation. Activation of T
cells occurs because the TCR is able to bind antigenic peptides
complexed with major histocompatibility complex-encoded molecules, and
to relay this extracellular stimulus to the intracellular signaling
machinery. Signal initiation from the ligand-bound TCR involves the
sequential activation of Src family (Lck,Fyn) and Syk family (ZAP-70)
protein tyrosine kinases (PTKs). These TCR-regulation PTKs, in tum,
catalyze phosphorylation events leading to the activation of
phospholipase PLC-gamma-l, Ras, and phosphatidylinositol-3 kinase
(PI-3K). In spite of the impressive advances in our understanding of
TCR function in recent years, the mechanism by which this receptor
couples to downstream signaling proteins, and the relative contributions
of these proteins to the T-cell activation program, are only partially
understood.
To further define the process of TCR-mediated signal transduction, Dr.
Abraham's group has created a novel set of cellular and molecular
reagents that will allow the application of powerful genetic approaches
to analyses of several key components of the post-receptor signaling
machinery. The human T-leukemic cell line, Jurkat, was chosen as a
well-established base model system for the proposed studies. The
principal readout for TCR signaling function will be a prototypical
nuclear response to TCR engagement, i.e., interleukin-2 (IL-2) gene
expression. The specific aims of the proposed project are: (1) To
study the mechanism of ZAP-70 activation and the roles of this PTK in
TCR signaling using a ZAP-70-negative Jurkat mutant as the cellular
model system. (2) To define the mechanism of PLC-gamma-l activation
by the TCR, and to determine the contributions of various PLC-gamma-l
subdomains to the signaling functions of this enzyme during T-cell
activation. (3) To examine the roles of PLC-gamma-l,Ras,and PI-3K in
IL-2 gene transcription using a virus-derived oncoprotein as a
polyfunctional signal transducer in T cells.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
KINASE TARGETS IN HYPOXIC CANCER CELLS
-
批准号:6923492
-
项目类别:
-
资助金额:$18.68万
-
财政年份:2005
-
负责人:ROBERT T ABRAHAM
-
依托单位:
Developmental Pilot Project 2
-
批准号:6990460
-
项目类别:
-
资助金额:$4.43万
-
财政年份:2004
-
负责人:ROBERT T ABRAHAM
-
依托单位:
Roles of ATM and ATR Kinases in DNA Damage Responses
-
批准号:6640664
-
项目类别:
-
资助金额:$39.65万
-
财政年份:2002
-
负责人:ROBERT T ABRAHAM
-
依托单位:
NEW TRANSLATION INITIATION INHIBITORS FOR CANCER THERAPY
-
批准号:6650587
-
项目类别:
-
资助金额:$25.04万
-
财政年份:2002
-
负责人:ROBERT T ABRAHAM
-
依托单位:
Roles of ATM and ATR Kinases in DNA Damage Responses
-
批准号:6555197
-
项目类别:
-
资助金额:$39.65万
-
财政年份:2002
-
负责人:ROBERT T ABRAHAM
-
依托单位:
Roles of ATM and ATR Kinases in DNA Damage Responses
-
批准号:6706268
-
项目类别:
-
资助金额:$39.65万
-
财政年份:2002
-
负责人:ROBERT T ABRAHAM
-
依托单位:
NEW TRANSLATION INITIATION INHIBITORS FOR CANCER THERAPY
-
批准号:6496689
-
项目类别:
-
资助金额:$25.04万
-
财政年份:2001
-
负责人:ROBERT T ABRAHAM
-
依托单位:
CELL CYCLE TARGETS FOR ANTICANCER DRUGS
-
批准号:6300373
-
项目类别:
-
资助金额:$16.56万
-
财政年份:2000
-
负责人:ROBERT T ABRAHAM
-
依托单位:
CELL CYCLE TARGETS FOR ANTICANCER DRUGS
-
批准号:6102644
-
项目类别:
-
资助金额:$16.56万
-
财政年份:1999
-
负责人:ROBERT T ABRAHAM
-
依托单位:
CELL-CYCLE TARGETS FOR ANTICANCER DRUGS
-
批准号:6269456
-
项目类别:
-
资助金额:$15.96万
-
财政年份:1998
-
负责人:ROBERT T ABRAHAM
-
依托单位:
CELLULAR PHARMACOLOGY OF RAPAMYCIN
-
批准号:6124431
-
项目类别:
-
资助金额:$21.11万
-
财政年份:1997
-
负责人:ROBERT T ABRAHAM
-
依托单位:
CELLULAR PHARMACOLOGY OF RAPAMYCIN
-
批准号:2448920
-
项目类别:
-
资助金额:$18.49万
-
财政年份:1997
-
负责人:ROBERT T ABRAHAM
-
依托单位:
CELLULAR PHARMACOLOGY OF RAPAMYCIN
-
批准号:2837767
-
项目类别:
-
资助金额:$20.49万
-
财政年份:1997
-
负责人:ROBERT T ABRAHAM
-
依托单位:
Cellular Pharmacology of Rapamycin
-
批准号:6574185
-
项目类别:
-
资助金额:$33.6万
-
财政年份:1997
-
负责人:ROBERT T ABRAHAM
-
依托单位:
CANCER CENTER SUPPORT GRANT
-
批准号:6768018
-
项目类别:
-
资助金额:$340.0万
-
财政年份:1997
-
负责人:ROBERT T ABRAHAM
-
依托单位:
Cellular Pharmacology of Rapamycin
-
批准号:6712826
-
项目类别:
-
资助金额:$33.6万
-
财政年份:1997
-
负责人:ROBERT T ABRAHAM
-
依托单位:
CELLULAR PHARMACOLOGY OF RAPAMYCIN
-
批准号:6617287
-
项目类别:
-
资助金额:$14.78万
-
财政年份:1997
-
负责人:ROBERT T ABRAHAM
-
依托单位:
CELL-CYCLE TARGETS FOR ANTICANCER DRUGS
-
批准号:6237156
-
项目类别:
-
资助金额:$15.36万
-
财政年份:1997
-
负责人:ROBERT T ABRAHAM
-
依托单位:
CELLULAR PHARMACOLOGY OF RAPAMYCIN
-
批准号:6329001
-
项目类别:
-
资助金额:$6.96万
-
财政年份:1997
-
负责人:ROBERT T ABRAHAM
-
依托单位:
SIGNAL TRANSDUCTION FROM THE T CELL ANTIGEN RECEPTOR
-
批准号:2184688
-
项目类别:
-
资助金额:$19.13万
-
财政年份:1992
-
负责人:ROBERT T ABRAHAM
-
依托单位:
海外基金